Cytokine profile characteristics of the cervical mucosa in women with HIV/HPV coinfection

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Human papillomavirus (HPV) is recognized as the primary cause of cervical cancer. In women living with HIV, HPV infection is associated with a 3- to 4-fold increased risk of developing cervical intraepithelial neoplasia and cancer compared to HIV-negative women, even with effective combination antiretroviral therapy. The host immune response is crucial in determining the course of HPV infection, as cytokines and chemokines play a key role in antiviral defense, shaping the immune response type and influencing the clinical progression of the disease.

The aim is to analyze studies assessing cytokine concentrations in the cervical mucosa and their impact on the progression of HPV infection in HIV-positive women.

A systematic review was conducted, including studies that evaluated cytokine and chemokine levels in HIV-positive women of reproductive age (≥18 years). Both cohort and cross-sectional studies were considered.

This review examines cytokine and chemokine levels in biopsy samples and cervical scrapes from women co-infected with HIV and HPV. The analysis highlights distinct cytokine profile characteristics, including interferon-gamma (IFN-γ), interleukin-10 (IL-10), tumor necrosis factor (TNF), interleukin-6 (IL-6), and macrophage inflammatory protein (MIP).

Understanding immune processes and their impact on HPV infection in HIV-positive women contributes to a better understanding of the disease pathogenesis and improves diagnostics, prevention, and treatment strategies. Given the increased risk of acquiring HPV infection and the subsequent development of cervical precancerous lesions and cancer in HIV-positive women, strengthening preventive measures and early detection efforts for HPV infection in this population should be considered.

Full Text

Restricted Access

About the authors

Ivan V. Vyalykh

Federal Scientific Research Institute of Viral Infections “Virome”

Author for correspondence.
Email: vyalykh_iv@niivirom.ru
ORCID iD: 0000-0002-3123-8359
SPIN-code: 9107-4118

Cand. Sci. (Veterinary)

Russian Federation, Yekaterinburg

References

  1. International Agency for Research on Cancer: Global Cancer Observatory. Available from: https://gco.iarc.fr/en
  2. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937
  3. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. International Journal of Cancer. 2011;128(4):927–935. doi: 10.1002/ijc.25396
  4. Kriek JM, Jaumdally SZ Masson L, et al. Female genital tract inflammation, HIV co–infection and persistent mucosal Human Papillomavirus (HPV) infections. Virology. 2016;493:247–254. doi: 10.1016/j.virol.2016.03.022
  5. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. Journal of Infectious Diseases. 2009;199(7):936–944. doi: 10.1086/597309
  6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. IARC monographs on the evaluation of carcinogenic risks to humans. 2012;100(Pt B):1–441.
  7. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? Journal of Pathology. 2014;234(4):431–435. doi: 10.1002/path.4424
  8. Rositch AF, Koshiol J, Hudgens M, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta-analysis. International Journal of Cancer. 2013;133(6):1271–1285. doi: 10.1002/ijc.27828
  9. Kedrova AG, Podistov YuI, Kuznetsov VV, et al. Role of antiviral therapy in the complex treatment of patients with epithelial dysplasias and preinvasive cancer of the cervix uten organization of researches. Obstetrics and Gynecology. 2006;(6):27–30. EDN: HZWZUF
  10. Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Global Health. 2021;9(2):e161–e169. doi: 10.1016/S2214-109X(20)30459-9
  11. Dianova TV, Sverdlova ES. Possible ways of prevention of cervical cancer in HIV-infected women. Siberian Medical Journal (Irkutsk). 2010;6:113–115. EDN: NCMINV
  12. Sverdlova ES, Dianova TV. Features of papillomavirus infection in HIV-infected women. Epidemiology and Infectious Diseases. 2012;17(4):9–11. doi: 10.17816/EID40631
  13. Lekoane KMB, Kuupiel D, Mashamba-Thompson TP, Ginindza TG. The interplay of HIV and human papillomavirus-related cancers in sub-Saharan Africa: Scoping review. Systematic reviews. 2020;9(1):88. doi: 10.1186/s13643-020-01354-1
  14. Kelly H, Weiss HA, Benavente Y, et al. Association of anti-retroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(1):e45–e58. doi: 10.1016/S2352-3018(17)30149-2
  15. Autenshlius AI, Lykov АP, Shkunov AN, et al. Evaluation of the inflammatory and antiinflammatory factors of immunity in women with genital cancer and epithelial dysplasia. Cytokines and Inflammation. 2008:7(2):18–22. EDN: TFVHIJ
  16. Khmel’nitskii OK. Cytological and histological diagnostics of diseases of the cervix and uterine body. Saint Petersburg; 2000. 151 p. (In Russ.)
  17. Prilepskaya VN, Rogovskaya SI, Kondrikov NI, Sukhikh GT. Papillomavirus infection: diagnosis, treatment, prevention: A manual for doctors. Moscow: MEDpress-inform; 2007. 32 p. (In Russ.)
  18. Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018;32(6):795–808. doi: 10.1097/QAD.0000000000001765
  19. Karim S, Souho T, Benlemlih M, Bennani B. Cervical cancer induction enhancement potential of chlamydia trachomatis: A systematic review. Current microbiology. 2018;75(12):1667–1674. doi: 10.1007/s00284-018-1439-7
  20. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature reviews. Cancer. 2002;2(5):342–350. doi: 10.1038/nrc798
  21. Lin W, Niu Z, Zhang H, et al. Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer. International journal of clinical and experimental pathology. 2019;12(9):3604–3612.
  22. Fernandes JV, Medeiros Fernandes TA, Azevedo JC, et al. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncology letters. 2015;9(3):1015–1026. doi: 10.3892/ol.2015.2884
  23. Olaitan A, Johnson MA, Reid WM, Poulter LW. Changes to the cytokine microenvironment in the genital tract mucosa of HIV+ women. Clinical and experimental immunology. 1998;112(1):100–104. doi: 10.1046/j.1365-2249.1998.00561.x
  24. Berti FCB, Pereira APL, Cebinelli GCM, et al. The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma. Cytokine and growth factor reviews. 2017;34:1–13. doi: 10.1016/j.cytogfr.2017.03.002
  25. Houlihan CF, Larke NL, Watson-Jones D, et al. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS. 2012;26:2211–2222. doi: 10.1097/QAD.0b013e328358d908
  26. Kobayashi A, Greenblatt RM, Anastos K, et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer research. 2004;64(18):6766–6774. doi: 10.1158/0008-5472.CAN-04-1091
  27. Nicol AF, Fernandes AT, Grinsztejn B, et al. Distribution of immune cell subsets and cytokine-producing cells in the uterine cervix of human papillomavirus (HPV)-infected women: Influence of HIV-1 coinfection. Diagnostic molecular pathology. 2005;14(1):39–47. doi: 10.1097/01.pas.0000143309.81183.6c
  28. Fernandes AP, Goncalves MA, Duarte G, et al. HPV16, HPV18, and HIV infection may influence cervical cytokine intralesional levels. Virology. 2005;334(2):294–298. doi: 10.1016/j.virol.2005.01.029
  29. Behbahani H, Walther-Jallow L, Klareskog E, et al. Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV–1 and human papillomavirus infection. Journal of acquired immune deficiency syndromes. 2007;45(1):9–19. doi: 10.1097/QAI.0b013e3180415da7
  30. Buckley N, Huber A, Lo Y, et al. Association of high-risk human papillomavirus with genital tract mucosal immune factors in HIV-infected women. American journal of reproductive immunology. 2016;75(2):146–154. doi: 10.1111/aji.12461
  31. Schindler S, Netto E, Deminco F, et al. Detection of cytokines in cervicovaginal lavage in HIV-infected women and its association with high-risk human papillomavirus. Front Immunol. 2024;15:1416204. doi: 10.3389/fimmu.2024.1416204
  32. Guha D, Chatterjee R. Cytokine levels in HIV infected and uninfected Indian women: Correlation with other STAs. Experimental and molecular pathology. 2009;86(1):65–68. doi: 10.1016/j.yexmp.2008.10.001
  33. Nicol AF, Nuovo GJ, Wang Y, et al. In situ detection of SOCS and cytokine expression in the uterine cervix from HIV/HPV coinfected women. Experimental and molecular pathology. 2006;81(1):42–47. doi: 10.1016/j.yexmp.2006.01.002
  34. Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer prevention research. 2016;9(12):895–905. doi: 10.1158/1940-6207.CAPR-16-0209
  35. Song SH, Lee JK, Lee NW, et al. Interferon-gamma (IFN-gamma): A possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecologic oncology. 2008;108(3):543–548. doi: 10.1016/j.ygyno.2007.11.006
  36. Peghini BC, Abdalla DR, Barcelos AC, et al. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Human immunology. 2012;73(9):920–926. doi: 10.1016/j.humimm.2012.06.003
  37. Kobayashi A, Weinberg V, Darragh T, Smith-McCune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal immunology. 2008;1(5):412–420. doi: 10.1038/mi.2008.33
  38. Wang Y, Yang J, Huang J, Tian Z. Tumor necrosis factor-α polymorphisms and cervical cancer: Evidence from a meta-analysis. Gynecologic and obstetric investigation. 2020;85(2):153–158. doi: 10.1159/000502955
  39. Li H, Chi X, Li R, et al. HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer. International journal of biological sciences. 2019;15(11):2438–2447. doi: 10.7150/ijbs.38146
  40. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nature reviews. Immunology. 2018;18(12):773–789. doi: 10.1038/s41577-018-0066-7

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Vyalykh I.V.